John A. Capobianco (H-index: 54, citations: over 13 000), “Upconverting Nanoparticles: A Platform for Drug Delivery, PDT, XPDT, Nanothermometry and Bioimaging”
Professor John A. Capobianco received his BSc from McMaster University, Canada and his PhD from the University of Geneva, Switzerland. He then worked as a Post-Doctoral Fellow at McGill University, Montreal until he joined the faculty of Concordia University, Montreal where is currently Professor of Chemistry, Concordia University Senior Research Chair in Nanoscience and Director of the Centre for Nanoscience Research. He is a Fellow of the Royal Society of Chemistry (UK) and the Provost’s Circle of Distinction, Concordia University. Professor Capobianco’s research interest is mainly on light matter interaction, the synthesis and physicochemical characterization of lanthanide doped nanomaterials. His current research focuses on upconversion for biomedical applications in bioimaging, diagnostic, therapeutic, cell targeting functionalities, nanothermometry, PDT and XPDT. His high-quality contributions have put Professor Capobianco in the limelight of international research and this has been materialized by a number of appointments as invited professor at a number of European universities, and numerous invitations at international conferences, and many collaborations with other research groups. Over 150 students, post-doctoral fellows and visiting scientists have carried out research in Professor Capobianco’s laboratory.
Thomas L. Mindt (H-index: 23, citations: 2 466), “Radiometal-Based Radiopharmaceuticals for Theranostic Approaches in Nuclear Medicine”
Prof. Dr. Thomas L. Mindt is the Head of the program line Imaging Biomarkers at the Ludwig Boltzmann Institute Applied Diagnostics. He completed a double major in Organic Chemistry and Biotechnology at the University of Applied Sciences ZHW Winterthur (Switzerland) and obtained a PhD in Organic Chemistry from Brown University (USA). Upon his return to Europe, he worked as a senior assistant in Radiopharmaceutical Sciences at the ETH in Zurich (Switzerland). In 2009, he accepted a call of the University of Basel (Switzerland) as an Assistant Professor in Radiopharmaceutical Chemistry and in 2015 he was promoted to Honorary Professor. In 2016, he moved to Vienna as a co-founder of the new Ludwig Boltzmann Institute Applied Diagnostics. Thomas L. Mindt’s research focuses on the interface of medicine and chemistry, in particular on the development of novel diagnostic (imaging) probes and therapeutics for applications in nuclear oncology. He is interested in utilizing metallic radionuclides in a theranostic approach, e.g. by developing novel methodologies for the radiolabelling of biologically active molecules to explore their potential in clinical applications. He is engaged internationally in the field of radiopharmaceutical sciences as a member of the Radiopharmacy and Scientific Program Committees of the European Association of Nuclear Medicine (EANM), board member of the European Society of Radiopharmacy and Radiopharmaceuticals, editorial board member of the journals. Nuclear Medicine and Biology (Elsevier) and Molecules (MDPI), and reviewer for different societies, funding agencies, and peer reviewed scientific journals. Thomas L. Mindt has authored and co-authored numerous publications, book chapters and patents.